retatrutide mechanism triple agonist glp-1 gip glucagon The Road towards Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Receptor - An Update retatrutide mechanism glp-1 gip glucagon

IR, insulin receptor

Dosing is protocol-led, adverse events are recorded, and clinicians can stop or adjust treatment if safety concerns arise

All dosages of danuglipron significantly reduced patients HbA1c and fasting blood glucose levels, with more pronounced weight loss effects observed in the 80 mg and 120 mg doses compared to the placebo group

Counting macros

Serious but Less Common Side Effects: Pancreatitis: There is a risk of pancreatitis (inflammation of the pancreas), which is typically associated with a history of pancreatic disorders

Effects of steatotic liver disease and cardiometabolic risk factors in MASLD on adverse pregnancy outcomes